Dr. Anthony W. Tolcher

Dr. Tolcher is CEO and Founder of NEXT OncologyTM, San Antonio, Texas, a Phase I group that seeks to transform early clinical trials. NEXT has grown to 6 sites worldwide, with Phase 1 units in San Antonio, Austin, Dallas, Texas, Fairfax, Virginia, and two sites in Spain, including Madrid and Barcelona. Previously, Dr. Tolcher served as President and Co-Founder of START LLC from 2008- 2018, with locations in San Antonio, Texas; Grand Rapids, Michigan; Madrid, Spain; and Shanghai, China.Dr. Tolcher is a medical oncologist with over 25 years of experience in early drug development and clinical trials.  He has been involved in many of the initial Phase I studies of new agents that subsequently were FDA-approved for the treatment of cancer, including pembrolizumab (Keytruda®), abemiciclib (Verzenio®) copanlisib (Aliqopa®), cemipilimab (Libtayo®), Durvalumab (Imfinzi®) trastuzumab emtansine (Kadcyla®), regorafenib (Stivarga®), liposomal vincristine (Marqibo®), cabazitaxel (Jevtana®), carfilzomib (Kyprolis®), gefitinib (Iressa®), erlotinib (Tarceva®), temsirolimus (Torisel®), pemetrexed (Alimta®), panitumumab (Vectibix®), ixasbepilone (Ixempra®), and eribulin (Halaven®). He is currently the principal investigator on over 20 phase I clinical studies and is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research, and Annals of Oncology.  He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program.  Dr. Tolcher has over 130 peer-reviewed publications in scientific journals, including Nature, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Oncology, and Clinical Cancer Research, and is an author of nine book chapters.